Genmab — November 2020
-
God morgen.
-
Asien: Fremgang til de fleste markeder - teknologi dykkerhttps://www.proinvestor.com/investornyt/669491/asien-fremgang-til-de-fleste-markeder-teknologi-dykker
-
38.000 medlemmer i nat.
https://www.facebook.com/groups/1552522675046712 -
Vores Genmabgruppe passerede 3.000 medlemmer https://www.facebook.com/groups/1814736572095032
-
Flot Helge! Det gør kursen på Genmab også snart
Godmorgen til jer alle -
Aktier/tendens: Ambu skuffer og Bavarian løfter på stor regnskabsdaghttps://www.proinvestor.com/investornyt/669501/aktier-tendens-ambu-skuffer-og-bavarian-lofter-pa-stor-regnskabsdag
-
33k warrants udnyttet til under kurs 100 - mon ikke vi kommer til at se noget skattedrevet udsalg i løbet af dagen i dag?
-
Tror jeg...ny dag truer..
-
BioNTech SE (BNTX) Q3 2020 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2020/11/11/biontech-se-bntx-q3-2020-earnings-call-transcript/
-
"Conditional activation of 4-1BB is crucial as clinical development of 4-1BB agonist has been hampered by severe liver toxicity." and later on "the reason for reduced liver toxicity is the conditional binding mechanism to 4-1BB, which means that the antibody has to be bound to PD-L1 in order to be able to bind to 4-1BB by a confirmational change"
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind